USFDA completes PAI of Cipla's Qidong unit

Cipla Limited has announced that a pre-approval inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of Cipla (Jiangsu) Pharmaceutical Co., Ltd. (subsidiary of the Company) located in Qidong, Jiangsu Province, China from 26th February, 2024 to 1st March, 2024. The inspection concluded with zero Form 483 observations.

Cipla completes transfer of Generics Business Undertaking

Cipla has completed the transfer of Generics Business Undertaking as a going concern on a slump sale basis to Cipla Pharma and Life Sciences Limited, a wholly owned subsidiary of the company on 1st March, 2024.

Cipla incorporates JV company in USA

Cipla has informed that that the JV partners namely Cipla (EU) Limited, wholly owned subsidiary of the Cipla in UK, with Kemwell Biopharma UK Limited and MNI Ventures have received confirmation of incorporation of joint venture company MKC Biotherapeutics from Secretary of State, Delaware, USA on February 29, 2024. The effective date of incorporation is 27^th February, 2024.